Corlieve Therapeutics, a Paris, France-based biotechnology company focused on developing novel therapeutics for severe neurological disorders, closed its seed financing of undisclosed amount.
The round was led by Kurma Partners and IDinvest Partners, with participation from Pureos Bioventures.
The company intends to use the funds for further development of its novel therapeutics.
Corlieve Therapeutics focuses on developing novel therapeutics for severe neurological disorders. Its lead program employs a novel AAV gene therapy approach for the treatment of refractory temporal lobe epilepsy (TLE), the most commonly diagnosed focal epilepsy in humans. The program is based on pioneering science from INSERM, CNRS, Aix Marseille University and the University of Bordeaux, and is being developed in collaboration with REGENXBIO Inc. (Maryland, US), a gene therapy company. In addition, Corlieve has licensed REGENXBIO’s NAV AAV9 technology for the TLE program.
The company is led by Chief Executive Officer Richard Porter, Ph.D., who brings over 25 years of neuroscience leadership experience in the pharmaceutical and biotech industries, including most recently as Chief Operating Officer of Therachon Holding AG until its acquisition by Pfizer in July 2019.
The board will consist of Vanessa Malier, Managing Partner at Kurma, Anja Harmeier, Partner at Pureos Bioventures and Olivier Danos, Ph.D., Chief Scientific Officer of REGENXBIO.